Ascentage Pharma Group Inc.

7 trials 6 recruiting Commercial sponsor

Filter these 7 trials by condition, phase, country and more.

Open in Search →

7 Registered trials

6 Recruiting

0 Completed trials

15 Countries active

19 Unique IMPs

N/A Results reported

Phase III

Phase I/II

Phase III: 6 Phase I/II: 1

Top indications

Myelodysplastic syndrome 1

Top IMPs

LISAFTOCLAX 5 ACALABRUTINIB 2 IBRUTINIB 2 OLVEREMBATINIB 2 ZANUBRUTINIB 2 AZACITIDINE 1 BOSUTINIB 1 RITUXIMAB 1

All trials

7 total

A study testing the new drug Lisaftoclax for newly diagnosed acute myeloid leukemia(GLORA-3) Pending

2024-516436-10-00 Phase III 3 countries LISAFTOCLAX
A Global Study Testing the New Drug Olverembatinib combined with chemotherapy for Patients with Newly Diagnosed Philadelphia Chromosome-Pos… Recruiting

2024-511496-14-00 Phase III 7 countries OLVEREMBATINIB
A Worldwide Study Testing the New Drug Lisaftoclax for Patients with Newly Diagnosed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma… Recruiting

2024-514084-26-00 Phase III 3 countries LISAFTOCLAX
A Phase Ib/II Study of APG-2575 as a Single Agent or in Combination with Other Therapeutic Agents in Patients with Relapsed and/or Refractor… Recruiting

2024-515654-25-00 Phase I/II 2 countries ACALABRUTINIB; IBRUTINIB; LISAFTOCLAX; RITUXIMAB; ZANUBRUTINIB
A study to evaluate the efficacy of APG-2575 (Lisaftoclax) plus azacitidine (AZA) vs. placebo plus AZA in newly diagnosed adult subjects wit… Recruiting

2024-517247-31-00 Phase III 13 countries AZACITIDINE; LISAFTOCLAX
A Worldwide Study Testing the New Drug Olverembatinib for Patients with Chronic Phase Chronic Myeloid Leukemia (POLARIS-2) Recruiting

2024-511495-32-00 Phase III 6 countries BOSUTINIB; OLVEREMBATINIB
A Global Multicenter, Open Label, Randomized Phase 3 Registrational Study of Lisaftoclax (APG-2575) in Previously Treated Patients with Chro… Recruiting

2023-508005-24-00 Phase III 11 countries ACALABRUTINIB; IBRUTINIB; LISAFTOCLAX; ZANUBRUTINIB

Showing 1–7 of 7 trials

← All sponsors A–Z